MX352949B - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX352949B
MX352949B MX2013003365A MX2013003365A MX352949B MX 352949 B MX352949 B MX 352949B MX 2013003365 A MX2013003365 A MX 2013003365A MX 2013003365 A MX2013003365 A MX 2013003365A MX 352949 B MX352949 B MX 352949B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
relates
present
pharmaceutical compositions
improved stability
Prior art date
Application number
MX2013003365A
Other languages
English (en)
Other versions
MX2013003365A (es
Inventor
Anders Nilsson
Kazimierz Wisniewski
Mattias Malm
Britta Siekmann
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352949(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2013003365A publication Critical patent/MX2013003365A/es
Publication of MX352949B publication Critical patent/MX352949B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invención se refiere a una composición acuosa caracterizada porque comprende de 0.05 mg/ml a 0.5 mg/ml de carbetocina o una sal farmacéuticamente activa de la misma, en donde el pH de la composición es de 5.5 a 5.9, y en donde la composición además comprende una antioxidante seleccionado del grupo que consiste en metionina, EDTA, o una combinación de metionina y EDTA.
MX2013003365A 2010-09-30 2011-09-29 Composicion farmaceutica. MX352949B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2013003365A MX2013003365A (es) 2013-07-29
MX352949B true MX352949B (es) 2017-12-15

Family

ID=43478408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003365A MX352949B (es) 2010-09-30 2011-09-29 Composicion farmaceutica.

Country Status (26)

Country Link
US (4) US9566311B2 (es)
EP (5) EP4374878A3 (es)
JP (2) JP6038797B2 (es)
KR (2) KR101919119B1 (es)
CN (4) CN107412728A (es)
AU (1) AU2011309762B2 (es)
BR (2) BR112013007362B1 (es)
CA (1) CA2812510A1 (es)
CY (2) CY1119245T1 (es)
DK (3) DK3222272T3 (es)
ES (3) ES2637988T3 (es)
HK (1) HK1246170A1 (es)
HR (2) HRP20211969T1 (es)
HU (3) HUE057187T2 (es)
IL (3) IL225238B (es)
JO (3) JO3400B1 (es)
LT (2) LT3222272T (es)
MX (1) MX352949B (es)
NZ (1) NZ609719A (es)
PL (3) PL3222272T3 (es)
PT (3) PT2621468T (es)
RS (2) RS62873B1 (es)
RU (2) RU2737264C2 (es)
SI (3) SI3222272T1 (es)
TW (6) TWI650134B (es)
WO (1) WO2012042371A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013260209A1 (en) * 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
CN112773765A (zh) * 2014-09-19 2021-05-11 辉凌公司 治疗普拉德-威利综合征的方法
RU2701199C2 (ru) 2014-10-01 2019-09-25 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
PL3200764T3 (pl) 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
SI3242676T1 (sl) 2015-01-07 2024-02-29 Tonix Pharma Limited Formulacije oksitocina, ki vsebujejo magnezij in načini uporabe
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
WO2017180781A1 (en) 2016-04-12 2017-10-19 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
WO2019030412A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
CN112839632A (zh) * 2018-09-20 2021-05-25 莱沃疗法公司 稳定的鼻内卡贝缩宫素制剂
CN112969450B (zh) 2018-09-20 2023-05-30 阿卡蒂亚药品公司 卡贝缩宫素药物产品及用于制备其的方法
CN109745544A (zh) * 2018-11-23 2019-05-14 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
WO2020128499A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
JP2023500763A (ja) 2019-11-04 2023-01-11 フェリング ベスローテン フェンノートシャップ 泌乳の改善のためのメロトシンの鼻腔内投与
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CA3214303A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
ES2265470T3 (es) 1997-11-18 2007-02-16 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
ATE477811T1 (de) 2002-10-03 2010-09-15 Neuropharmacology Services Llc Oxytocin zur behandlung von autismus und asperger-syndrom
EP2174663A1 (en) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
AU2004218369A1 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
MY161661A (en) 2007-07-02 2017-04-28 Sime Darby Malaysia Berhad Vegetable fat blend and edible products containing such a fat blend
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
PT2260053E (pt) 2008-03-31 2014-08-29 Ferring Bv Análogos de oxitocina
CA2738715C (en) * 2008-10-15 2013-07-16 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof

Also Published As

Publication number Publication date
KR20130136467A (ko) 2013-12-12
AU2011309762A1 (en) 2013-04-04
SI2621468T1 (sl) 2017-10-30
DK3246018T3 (da) 2022-01-17
LT3222272T (lt) 2021-12-27
CY1124924T1 (el) 2023-01-05
CN107412728A (zh) 2017-12-01
JP6250770B2 (ja) 2017-12-20
TW201940188A (zh) 2019-10-16
BR112013007362A2 (pt) 2016-07-12
EP2621468A2 (en) 2013-08-07
AU2011309762B2 (en) 2014-07-17
JOP20180103A1 (ar) 2019-01-30
HK1246170A1 (zh) 2018-09-07
WO2012042371A2 (en) 2012-04-05
JOP20180102A1 (ar) 2019-01-30
TWI650134B (zh) 2019-02-11
KR102102664B1 (ko) 2020-04-22
US20230124105A1 (en) 2023-04-20
IL245328A0 (en) 2016-06-30
SI3222272T1 (sl) 2022-01-31
JP2017048226A (ja) 2017-03-09
PT2621468T (pt) 2017-09-08
EP3936117A1 (en) 2022-01-12
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
IL245326A0 (en) 2016-06-30
HUE056835T2 (hu) 2022-03-28
HUE034367T2 (en) 2018-02-28
RS62873B1 (sr) 2022-02-28
LT2621468T (lt) 2017-11-27
EP4374878A3 (en) 2024-07-24
CN103124554A (zh) 2013-05-29
TW201605466A (zh) 2016-02-16
RU2016143751A3 (es) 2020-01-16
JP6038797B2 (ja) 2016-12-07
US20130210746A1 (en) 2013-08-15
MX2013003365A (es) 2013-07-29
EP2621468B1 (en) 2017-06-14
IL225238B (en) 2018-07-31
TW201605465A (zh) 2016-02-16
JO3400B1 (ar) 2019-10-20
BR122021001123B1 (pt) 2021-05-18
US20170106043A1 (en) 2017-04-20
HRP20171256T1 (hr) 2017-10-20
US20170106044A1 (en) 2017-04-20
RU2604690C2 (ru) 2016-12-10
CN107080832A (zh) 2017-08-22
EP4374878A2 (en) 2024-05-29
ES2902418T3 (es) 2022-03-28
RU2013112666A (ru) 2014-11-10
TW202112389A (zh) 2021-04-01
DK3222272T3 (da) 2022-01-24
IL245326B (en) 2021-04-29
IL245328B (en) 2022-04-01
TWI750934B (zh) 2021-12-21
ES2637988T3 (es) 2017-10-18
PL3222272T3 (pl) 2022-03-07
RS56220B1 (sr) 2017-11-30
TWI680773B (zh) 2020-01-01
EP3222272B1 (en) 2021-11-03
TWI661834B (zh) 2019-06-11
WO2012042371A3 (en) 2013-04-04
EP3246018B1 (en) 2021-11-03
TWI532507B (zh) 2016-05-11
EP3246018A1 (en) 2017-11-22
NZ609719A (en) 2014-07-25
IL225238A0 (en) 2013-06-27
DK2621468T3 (en) 2017-09-11
JOP20180102B1 (ar) 2022-03-14
US9566311B2 (en) 2017-02-14
PL2621468T3 (pl) 2017-11-30
EP3222272A1 (en) 2017-09-27
CA2812510A1 (en) 2012-04-05
RU2737264C2 (ru) 2020-11-26
CN107080832B (zh) 2021-05-07
PT3246018T (pt) 2022-01-13
KR101919119B1 (ko) 2018-11-15
HUE057187T2 (hu) 2022-04-28
BR112013007362B1 (pt) 2021-05-25
SI3246018T1 (sl) 2022-02-28
JP2013543492A (ja) 2013-12-05
ES2905561T3 (es) 2022-04-11
HRP20211969T1 (hr) 2022-03-18
TWI746951B (zh) 2021-11-21
JOP20180103B1 (ar) 2022-03-14
TW201729797A (zh) 2017-09-01
CY1119245T1 (el) 2018-02-14
PL3246018T3 (pl) 2022-05-02
RU2016143751A (ru) 2018-12-18
CN104906032A (zh) 2015-09-16
KR20180123599A (ko) 2018-11-16

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MX2012015188A (es) Composiciones de liberacion controlada con efecto de alimentos reducido.
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2013002417A (es) Composiciones pesticidas.
IN2015DN00960A (es)
MX2013002264A (es) Composiciones pesticidas.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EA201590887A1 (ru) Композиция
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
MX2014002625A (es) Nuevas composiciones para la produccion de poliamidas coladas.
MY149433A (en) Nutritional compositions containing punicalagins
MY165088A (en) Pharmaceutical compositions comprising alisporivir
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
HK1151718A1 (en) Flupentixol compositions
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
MX351789B (es) Nueva composicion para la preparación de poliamidas de fundido..
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
GB201005403D0 (en) Novel pharmaceutical compositions
TN2010000225A1 (en) Injectable liquid paracetamol formulation

Legal Events

Date Code Title Description
FG Grant or registration